

# ABBOTT ACQUISITION OF ALERE

Transaction will significantly advance Abbott's diagnostics presence and leadership



<b>Annual Sales</b>	Abbott: \$20.4 billion Total Diagnostics: \$4.6 billion Point of Care Diagnostics: \$473 million	\$2.5 billion
<b>Headquarters</b>	Abbott Park, Ill., USA	Waltham, Mass., USA
<b>Global Reach</b>	150 countries	100+ countries
<b>Diagnostics Leadership</b>	Leader in Immunoassay and Blood Screening	Leading Point of Care company with broad menu of rapid, benchtop and hand-held Infectious Disease, Molecular, Cardiometabolic, Toxicology tests
<b>Diagnostics Businesses</b>	Immunoassay, Clinical Chemistry, Blood Screening, Hematology, Point of Care, Molecular	Point of Care
<b>Legacy of Innovation</b>	<ul style="list-style-type: none"> <li>• First test to detect HIV</li> <li>• First companion diagnostics test</li> <li>• First FDA-approved hepatitis C genotype test</li> </ul>	<ul style="list-style-type: none"> <li>• First CLIA-waived molecular test (flu)</li> <li>• First fully portable CD4 platform</li> <li>• First wireless POC solution for blood gases, electrolytes and metabolites</li> </ul>